Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug 11:12:715036.
doi: 10.3389/fimmu.2021.715036. eCollection 2021.

Clinical Efficacy and Safety of Eculizumab for Treating Myasthenia Gravis

Hai Xiao  1 , Ka Wu  2 , Xiaoliu Liang  3 , Rong Li  4 , Keng Po Lai  4
Affiliations

Clinical Efficacy and Safety of Eculizumab for Treating Myasthenia Gravis

Hai Xiao et al. Front Immunol. .

Abstract

Myasthenia gravis (MG) is an autoimmune disease primarily mediated by acetylcholine receptor antibodies (AChR-Ab), cellular immune dependence, and complement system involvement. Since the AChR on the postsynaptic membrane is destroyed by an immune attack, sufficient endplate potential cannot be generated, resulting in the development of a synaptic transmission disorder at the neuromuscular junction and in muscle weakness. The role of the complement system in MG has been demonstrated in animal models and clinical tests, and it has been determined that complement inhibition in patients with MG can prevent disease induction and reverse its progression. Eculizumab is a humanized monoclonal antibody that inhibits the cleavage of complement protein C5 and prevents autoimmune damage; additionally, it has received subsequent approval by the Federal Drug Administration of the United States for MG treatment. However, various concerns regarding the use of eculizumab persist. In this review, we have discussed the treatment time, cost effectiveness, long-term efficacy, and tolerability of eculizumab for MG treatment. We have also summarized historical information and have presented perspectives on this new therapeutic modality.

Keywords: clinical; eculizumab; generalized myasthenia gravis; mechanism; systematic review.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Pharmaceutical effects of eculizumab for treating myasthenia gravis.
Figure 2
Figure 2
Clinical trials of eculizumab in patients with myasthenia gravis.
See this image and copyright information in PMC

References

    1. Evoli A, Padua L. Diagnosis and Therapy of Myasthenia Gravis With Antibodies to Muscle-Specific Kinase. Autoimmun Rev (2013) 12(9):931–5. 10.1016/j.autrev.2013.03.004 - DOI - PubMed
    1. Li Y, Chu L, Zhang Y. Advances in Research on the Mechanism of Myasthenia Gravis Immunology. Chin J Neuroimmunol Neurol (2015) 03:209–14. 10.3969/j.issn.1006-2963.2015.03.013 - DOI
    1. Luo J, Lindstrom J. AChR-Specific Immunosuppressive Therapy of Myasthenia Gravis. Biochem Pharmacol (2015) 97:609–19. 10.1016/j.bcp.2015.07.011 - DOI - PubMed
    1. Shen Y. Comparison of the Efficacy of Gracilis and Glucocorticoids in the Treatment of Myasthenia Gravis. Chin Foreign Med Res (2014) 03:136–7.
    1. Dong H, Qiao W. Progress in Research and Treatment of Myasthenia Gravis Antibody. Clin Res Trad Chin Med (2017) 04:145–8. 10.3969/j.issn.1674-7860.2017.04.074 - DOI

Publication types

MeSH terms

Substances